» Articles » PMID: 37072346

Naive T Cells Inhibit the Outgrowth of Intractable Antigen-activated Memory T Cells: Implications for T-cell Immunotherapy

Abstract

Background: The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr virus (EBV)-specific T cells (EBVSTs) for the treatment of EBV-positive lymphoma. EBVSTs could not be manufactured from almost one-third of patients, either because they failed to expand, or they expanded, but lacked EBV specificity. We identified an underlying cause of this problem and established a clinically feasible approach to overcome it.

Methods: CD45RO+CD45RA- memory compartment residing antigen-specific T cells were enriched by depleting CD45RA positive (+) peripheral blood mononuclear cells (PBMCs) that include naïve T cells, among other subsets, prior to EBV antigen stimulation. We then compared the phenotype, specificity, function and T-cell receptor (TCR) Vβ repertoire of EBVSTs expanded from unfractionated whole (W)-PBMCs and CD45RA-depleted (RAD)-PBMCs on day 16. To identify the CD45RA component that inhibited EBVST outgrowth, isolated CD45RA+ subsets were added back to RAD-PBMCs followed by expansion and characterization. The in vivo potency of W-EBVSTs and RAD-EBVSTs was compared in a murine xenograft model of autologous EBV+ lymphoma.

Results: Depletion of CD45RA+ PBMCs before antigen stimulation increased EBVST expansion, antigen-specificity and potency in vitro and in vivo. TCR sequencing revealed a selective outgrowth in RAD-EBVSTs of clonotypes that expanded poorly in W-EBVSTs. Inhibition of antigen-stimulated T cells by CD45RA+ PBMCs could be reproduced only by the naïve T-cell fraction, while CD45RA+ regulatory T cells, natural killer cells, stem cell memory and effector memory subsets lacked inhibitory activity. Crucially, CD45RA depletion of PBMCs from patients with lymphoma enabled the outgrowth of EBVSTs that failed to expand from W-PBMCs. This enhanced specificity extended to T cells specific for other viruses.

Conclusion: Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation.

Citing Articles

Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo.

Palianina D, Mietz J, Stuhler C, Arnold B, Bantug G, Munz C Sci Adv. 2024; 10(34):eado2048.

PMID: 39178248 PMC: 11343021. DOI: 10.1126/sciadv.ado2048.


Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30 lymphoma.

Quach D, Ganesh H, Briones Y, Nouraee N, Ma A, Hadidi Y Mol Ther Oncol. 2024; 32(2):200814.

PMID: 38966037 PMC: 11223124. DOI: 10.1016/j.omton.2024.200814.


B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.

Yeo S, Kua L, Tan J, Lim J, Wong F, Delos Santos M Cancer Res Commun. 2024; 4(6):1410-1429.

PMID: 38717140 PMC: 11149603. DOI: 10.1158/2767-9764.CRC-23-0538.


Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma.

Sharma S, Mehta N, Sauer T, Rollins L, Dittmer D, Rooney C Blood Adv. 2024; 8(13):3360-3371.

PMID: 38640255 PMC: 11255116. DOI: 10.1182/bloodadvances.2023012183.


Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.

Sharma S, Sauer T, Omer B, Shum T, Rollins L, Rooney C Int J Mol Sci. 2023; 24(21).

PMID: 37958791 PMC: 10649234. DOI: 10.3390/ijms242115806.

References
1.
Beilhack A, Schulz S, Baker J, Beilhack G, Wieland C, Herman E . In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005; 106(3):1113-22. PMC: 1895168. DOI: 10.1182/blood-2005-02-0509. View

2.
Hoffmann P, Eder R, Boeld T, Doser K, Piseshka B, Andreesen R . Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006; 108(13):4260-7. DOI: 10.1182/blood-2006-06-027409. View

3.
Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, Rickinson A . Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001; 75(18):8649-59. PMC: 115110. DOI: 10.1128/jvi.75.18.8649-8659.2001. View

4.
Nikolich-Zugich J, Slifka M, Messaoudi I . The many important facets of T-cell repertoire diversity. Nat Rev Immunol. 2004; 4(2):123-32. DOI: 10.1038/nri1292. View

5.
Papadopoulou A, Gerdemann U, Katari U, Tzannou I, Liu H, Martinez C . Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014; 6(242):242ra83. PMC: 4181611. DOI: 10.1126/scitranslmed.3008825. View